Amprenavir
|
The antiacid decreases the absorption of amprenavir
|
Atazanavir
|
This gastric pH modifier decreases the levels/effects of atazanavir
|
Chloroquine
|
The antiacid decreases the absorption of chloroquine
|
Ciprofloxacin
|
Formation of non-absorbable complexes
|
Clodronate
|
Formation of non-absorbable complexes
|
Dapsone
|
Formation of non-absorbable complexes
|
Delavirdine
|
The antiacid decreases the effect of delavirdine
|
Demeclocycline
|
Formation of non-absorbable complexes
|
Doxycycline
|
Formation of non-absorbable complexes
|
Etidronic acid
|
Formation of non-absorbable complexes
|
Fosamprenavir
|
The antiacid decreases the absorption of amprenavir
|
Gatifloxacin
|
Formation of non-absorbable complexes
|
Gemifloxacin
|
Formation of non-absorbable complexes
|
Grepafloxacin
|
Formation of non-absorbable complexes
|
Ibandronate
|
Formation of non absorbable complexes
|
Indinavir
|
The antacid decreases the absorption of indinavir
|
Itraconazole
|
The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption.
|
Ketoconazole
|
The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption.
|
Levofloxacin
|
Formation of non-absorbable complexes
|
Minocycline
|
Formation of non-absorbable complexes
|
Moxifloxacin
|
Formation of non-absorbable complexes
|
Norfloxacin
|
Formation of non-absorbable complexes
|
Ofloxacin
|
Formation of non-absorbable complexes
|
Tiludronate
|
The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
|
Trovafloxacin
|
Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.
|